Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
31.20
+0.04 (0.13%)
At close: Dec 5, 2025, 4:00 PM EST
30.69
-0.51 (-1.63%)
After-hours: Dec 5, 2025, 7:56 PM EST
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Arcutis Biotherapeutics stock ranges from a low of $15 to a high of $37. The average analyst price target of $24.83 forecasts a -20.42% decrease in the stock price over the next year.
Price Target: $24.83 (-20.42%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $32 → $37 | Buy | Maintains | $32 → $37 | +18.59% | Nov 28, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $19 → $29 | Hold | Maintains | $19 → $29 | -7.05% | Oct 30, 2025 |
| Needham | Needham | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | -3.85% | Oct 28, 2025 |
| Needham | Needham | Strong Buy Maintains $20 → $22 | Strong Buy | Maintains | $20 → $22 | -29.49% | Aug 7, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $18 | Hold | Initiates | $18 | -42.31% | Jul 25, 2025 |
Financial Forecast
Revenue This Year
364.60M
from 196.54M
Increased by 85.51%
Revenue Next Year
476.67M
from 364.60M
Increased by 30.74%
EPS This Year
-0.20
from -1.16
EPS Next Year
0.37
from -0.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 379.4M | 493.6M | ||||
| Avg | 364.6M | 476.7M | ||||
| Low | 346.5M | 452.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 93.0% | 35.4% | ||||
| Avg | 85.5% | 30.7% | ||||
| Low | 76.3% | 24.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.15 | 0.50 | ||||
| Avg | -0.20 | 0.37 | ||||
| Low | -0.30 | 0.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.